update
BDSI delays Onsolis “relaunch” to enable reformulation
BioDelivery Sciences International (BDSI) has postponed the ‘relaunch’ of its pain drug Onsolis to give it more time to modify the formulation.
News & Analysis on the Clinical Development and Manufacture of Large Molecule Drugs